Literature DB >> 6093511

Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.

B E Scully, K P Fu, H C Neu.   

Abstract

The pharmacokinetics of ceftriaxone were evaluated in eight adults after doses of 1 g administered by intravenous infusion and 1 and 0.5 g administered by intramuscular injection. Mean peak plasma concentrations were 168 micrograms/ml for 1 g given intravenously, 81 micrograms/ml for 1 g given intramuscularly, and 46 micrograms/ml for 0.5 g intramuscularly. Plasma concentrations were similar by both high pressure liquid chromatographic and microbiologic methods. The plasma half-lives were 7.6 and 8.3 hours, respectively, for the intravenous infusion and intramuscular injection. Plasma concentrations were equal for the 1 g intravenous and intramuscular routes by 2.5 hours. Plasma concentrations exceeded the minimal inhibitory concentrations (MICs) of most aerobic gram-positive and gram-negative organisms with the exception of Pseudomonas aeruginosa and Acinetobacter species for 24 hours. Urinary concentrations exceeded 100 micrograms/ml for 24 hours for the 1-g doses and for 12 hours for the 0.5-g dose. Urinary recovery of ceftriaxone within 24 hours was 40 percent for intravenous infusion and 33 and 34 percent for the intramuscular injection. A single 1-g dose daily will exceed the MICs of most staphylococcal and streptococcal species and Enterobacteriaceae for 12 to 24 hours.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093511

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Pyelonephritis in pregnancy: treatment options for optimal outcomes.

Authors:  D A Wing
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 5.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Ceftriaxone in the treatment of chronic donovanosis in central Australia.

Authors:  A Merianos; M Gilles; J Chuah
Journal:  Genitourin Med       Date:  1994-04

7.  Once-daily ceftriaxone out-patient therapy for superficial wound infection following major orthopaedic operation.

Authors:  S S Nathan; G Williams; N Hounsel; S P Hughes
Journal:  Eur J Orthop Surg Traumatol       Date:  1996-05

8.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

9.  Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

Authors:  R Van Dalen; T B Vree; I M Baars
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.

Authors:  Satofumi Iida; Haruki Kinoshita; Takehiko Kawanishi; Masahiro Hayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.